Ed Hurwitz is an accomplished biotech executive and investor with more than 30 years of industry experience. He is currently Founder and Managing Director of Precision Bioventures, LLC, an investment advisory firm where he founded and seeded start-up biotechnology companies, including Viewpoint Therapeutics. Previously, Ed was a Managing Director at MPM Capital, where he led the firm’s venture investments in multiple biotechnology companies. Ed currently serves as Chairman of MPM portfolio companies BioIntervene and Protego, and represents MPM on the Boards of ProRavel and Arialys. He is also on the boards of Dyne Therapeutics (NASDAQ: DYN) and MacroGenics (NASDAQ: MGNX). Prior to MPM, Ed was a Director at Alta Partners, where he led 12 successful investments including Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), FoldRx Pharmaceuticals (acquired by Pfizer), and Taligen Therapeutics (acquired by Alexion). Over the course of his career, he has been a Senior Vice President and CFO of Affymetrix, a microarray pioneer, and a biotech research analyst for Robertson Stephens & Company and Smith Barney Shearson. He also practiced law at Cooley Godward LLP. Ed earned his J.D. and M.B.A. degrees from the University of California, Berkeley’s Boalt School of Law and Haas School of Business and his B.A. in molecular biology from Cornell University.